BIOAVAILABILITY OF URSOCARB VS ACTIGALL IN CHRONIC CHOLESTATIC LIVER DISEASE

本研究的目的是确定阿司匹林的生物利用度 聚合物涂层和缓冲UDCA(URSOCARB)与Actigalon的比较 UDCA在胆汁中的浓缩百分比、UDCA的比例和浓度 并比较这两种检测结果之间的差异 囊性纤维化和慢性肝病患者的治疗。 在使用ACTIGALL进行为期四周的治疗后，每天15-30毫克/公斤(见 分两次剂量)，受试者将进行胆汁样本(串试验)， 采集了血液和尿液。然后受试者将进行24小时的淘汰赛 周期，并改用URSOCARB，每天15-30毫克/公斤(分两次给药 分剂量)。在四周的治疗结束后，受试者将 采集胆汁(串试验)、血液和尿液样本。这个 胆汁样本将被分析UDCA的浓缩程度。 将测量血清和尿液排泄量；增加肾排出量 UDCA将支持UDCA在 肠道可增加吸收和生物利用度。

The objective of this study is to determine the bioavailability of a polymer coated and buffered UDCA (URSOCARB) as compared to ACTIGALL on percent UDCA enrichment in the bile, proportion and concentration of UDCA in serum and compare the differences between the results for these two treatments in patients with cystic fibrosis and chronic liver disease. Following a four-week treatment with ACTIGALL at 15-30 mg/kg/day (given in two divided doses), the subjects will have samples of bile (string test), blood and urine collected. The subjects will then have a 24-hour wash-out period, and be switched to URSOCARB at 15-30 mg/kg/day (given in two divided doses). At the end of four weeks of treatment, the subjects will have samples of bile (string test), blood and urine collected. The samples of bile will be analyzed for the degree of UDCA enrichment. Serum and urinary excretion will be measured; enhanced renal output of UDCA will support the contention that greater solubility of UDCA in the intestine increases absorption and bioavailability.